TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19754502

Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 258
Study: 19755203

Group type: EXPERIMENTAL
Intervention: Heart transplantation referral
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Dilated cardiomyopathy
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: NYHA class IV
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Pulmonary artery systolic pressure ≥50 mmHg
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Pulmonary capillary pressure ≥25 mmHg
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction ≤17%
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Functional NYHA class IV
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Systemic systolic arterial pressure ≤90 mmHg
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: hsCRP≥6.5 mg/L
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: NTpro-BNP≥4302 pg/mL
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Na serum level≤135 mEq/L
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: BMI≤23.8
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: HFSS≤7.19
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Sodium plasma levels ≤135 mEq/L
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Sodium plasma levels ≤135 mEq/L + NTpro-BNP≥4302 pg/mL
Number of subjects: 983
Study: 19755366

Group type: EXPERIMENTAL
Intervention: Scoring system for authorship based on contributions to the study
Number of subjects: 0
Study: 19755674

Group type: EXPERIMENTAL
Intervention: More than 5% residual normal plasma cells (N-PCs/BMPCs)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Less than or equal to 5% residual normal plasma cells (N-PCs/BMPCs)
Number of subjects: 594
Study: 19757984

Group type: EXPERIMENTAL
Intervention: Post-bronchodilator FEV(1)/FVC ratio < or = 0.70
Number of subjects: 100

Group type: COMPARATOR
Intervention: Post-bronchodilator FEV(1)/FVC ratio > 0.70
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Self-reported dyspnea
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Discussion with doctor about cough
Number of subjects: 100
Study: 19758095

Group type: EXPERIMENTAL
Intervention: Safe water storage vessels, hygiene education, and bleach for household water treatment (Cohort B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (Cohort A)
Number of subjects: 0
Study: 19760233

Group type: EXPERIMENTAL
Intervention: CT imaging in patients with >or=1 positive predictors (855 patients)
Number of subjects: 1047

Group type: COMPARATOR
Intervention: No CT imaging in patients with no positive predictors (192 patients)
Number of subjects: 1047
Study: 19760338

Group type: EXPERIMENTAL
Intervention: PET
Number of subjects: 3019

Group type: EXPERIMENTAL
Intervention: CTA
Number of subjects: 3019

Group type: EXPERIMENTAL
Intervention: SPECT
Number of subjects: 3019

Group type: EXPERIMENTAL
Intervention: All imaging arms (PET, CTA, SPECT)
Number of subjects: 3019
Study: 19766264

Group type: EXPERIMENTAL
Intervention: Obese children (Ob)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Obese children (Ob) after 500-kcal liquid meal
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Obese children (Ob) after 1-year lifestyle intervention
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Weight status changes in Obese children (Ob)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Craniopharyngioma patients (CP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: MC4Rmut patients
Number of subjects: 52
Study: 19767508

Group type: EXPERIMENTAL
Intervention: Interim PET scans reviewed by expert panel
Number of subjects: 38
Study: 19769536

Group type: EXPERIMENTAL
Intervention: Azithromycin plus artesunate (AZ+AS)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 261
Study: 19770418

Group type: EXPERIMENTAL
Intervention: Surgery and perioperative INGN 201 gene therapy
Number of subjects: 13
Study: 19771175

Group type: EXPERIMENTAL
Intervention: SNP rs3822086
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: SNP rs3775444
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: 7-SNP haplotype including rs3822086
Number of subjects: 239
Study: 19771508

Group type: EXPERIMENTAL
Intervention: Epirubicin and docetaxel (2 or 3 weekly intervals)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Post-treatment tumor cellularity
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline PR levels
Number of subjects: 50
Study: 19773266

Group type: EXPERIMENTAL
Intervention: CD20 positivity over 20%
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: CD20 positivity over 20% in patients with WBC over 30x10(9)/L
Number of subjects: 143
Study: 19773371

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg b.i.d.
Number of subjects: 31
Study: 19773418

Group type: EXPERIMENTAL
Intervention: Rapamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19775921

Group type: EXPERIMENTAL
Intervention: rhGAA (recombinant human GAA) at a cumulative dose of 20 or 40 mg/kg/2 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: rhGAA (recombinant human GAA)
Number of subjects: 32
Study: 19776145

Group type: EXPERIMENTAL
Intervention: Total osteocalcin
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Carboxylated osteocalcin
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Uncarboxylated osteocalcin
Number of subjects: 348
Study: 19779040

Group type: EXPERIMENTAL
Intervention: Dasatinib treatment
Number of subjects: 1043
Study: 19780691

Group type: EXPERIMENTAL
Intervention: Telemedicine case management intervention
Number of subjects: 10
Study: 19780860

Group type: EXPERIMENTAL
Intervention: HLA-B*5701 assessment
Number of subjects: 1494
Study: 19782361

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg per day for one year
Number of subjects: 19
Study: 19782922

Group type: EXPERIMENTAL
Intervention: Coronary angiography
Number of subjects: 54
Study: 19783666

Group type: EXPERIMENTAL
Intervention: Population participants without CVD
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Population participants with CVD
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Hospital patients with CAD
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: All groups with spirometrically confirmed AL
Number of subjects: 621
Study: 19786468

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (enoxaparin or nadroparin)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Delayed-type hypersensitivity reactions
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Body mass index greater than 25
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Duration of heparin therapy longer than 9 days
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 320
Study: 19786617

Group type: EXPERIMENTAL
Intervention: (131)I-BC8 antibody (Ab; BC8) plus fludarabine and 2 Gy total body irradiation
Number of subjects: 58
Study: 19786667

Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg/d plus bortezomib 1.0 mg/m(2)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus bortezomib
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Dexamethasone added for progressive disease
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 38
Study: 19786927

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses for monthly continuous wear (CW)
Number of subjects: 205
Study: 19788468

Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 0
Study: 19788755

Group type: EXPERIMENTAL
Intervention: Community care coordinators (CCCs) providing care every three months in clinics and monthly in the community; CCCs underwent intensive training and mentoring.
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard of care with monthly clinic visits.
Number of subjects: 190
Study: 19789316

Group type: EXPERIMENTAL
Intervention: SGN-30 (4 mg/kg to 12 mg/kg, i.v. every 3 weeks for six doses, with potential for two additional courses)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: SGN-30
Number of subjects: 23
Study: 19793395

Group type: EXPERIMENTAL
Intervention: AUDS group
Number of subjects: 32

Group type: COMPARATOR
Intervention: MDE group
Number of subjects: 32
Study: 19793856

Group type: COMPARATOR
Intervention: Acute weight restoration in AN patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1-year weight maintenance in AN patients
Number of subjects: 30
Study: 19796970

Group type: EXPERIMENTAL
Intervention: Total cross-sectional area (CSA) of small pulmonary vessels < 5 mm²
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Total cross-sectional area (CSA) of small pulmonary vessels 5-10 mm²
Number of subjects: 191
Study: 19796996

Group type: EXPERIMENTAL
Intervention: Transoral endoscopic restrictive implant system
Number of subjects: 0
Study: 19797219

Group type: EXPERIMENTAL
Intervention: Visual acuity assessment using ETDRS charts
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: GA size quantified in digital fundus autofluorescence images
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: GA progression rate assessment
Number of subjects: 78
Study: 19797518

Group type: EXPERIMENTAL
Intervention: Interphase fluorescence in situ hybridization (I-FISH) with cutoff value of less than 1% positive nuclei.
Number of subjects: 664

Group type: COMPARATOR
Intervention: Chromosome banding analysis (CBA)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: I-FISH with less than 1% positive nuclei
Number of subjects: 664

Group type: COMPARATOR
Intervention: I-FISH with 1% to 5% positive nuclei
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: CCgR with I-FISH less than 1%
Number of subjects: 664

Group type: COMPARATOR
Intervention: CCgR with I-FISH 1% to 5%
Number of subjects: 664
Study: 19797573

Group type: EXPERIMENTAL
Intervention: Provocative landing position
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Exaggerated provocative landing position
Number of subjects: 25

Group type: COMPARATOR
Intervention: Safe landing position
Number of subjects: 25
Study: 19799842

Group type: EXPERIMENTAL
Intervention: S. aureus conjugate vaccine (StaphVAX) comprised of capsular polysaccharides 5 and 8 (CP5, CP8)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: S. aureus conjugate vaccine (StaphVAX)
Number of subjects: 88
Study: 19801505

Group type: EXPERIMENTAL
Intervention: Cardiac T2* magnetic resonance <10 ms
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Cardiac T2* magnetic resonance <20 ms
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Cardiac T2* magnetic resonance
Number of subjects: 652
Study: 19801583

Group type: EXPERIMENTAL
Intervention: Lean patients with OSA
Number of subjects: 54

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study: 19802379

Group type: EXPERIMENTAL
Intervention: Interactive patient groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community health workers (CHWs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Widespread implementation of CHWs
Number of subjects: 0
Study: 19802383

Group type: EXPERIMENTAL
Intervention: As+SMP
Number of subjects: 800

Group type: COMPARATOR
Intervention: PZQ
Number of subjects: 800
Study: 19805455

Group type: EXPERIMENTAL
Intervention: rHuPH20-facilitated subcutaneous rehydration
Number of subjects: 51
Study: 19805597

Group type: EXPERIMENTAL
Intervention: HOME Injury Survey
Number of subjects: 163
Study: 19806596

Group type: EXPERIMENTAL
Intervention: Sorafenib as adjuvant treatment
Number of subjects: 0
Study: 19808143

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 327
Study: 19808270

Group type: EXPERIMENTAL
Intervention: Day of admission (weekdays vs. weekends)
Number of subjects: 48612

Group type: EXPERIMENTAL
Intervention: Thursday and Friday admissions
Number of subjects: 48612
Study: 19808511

Group type: EXPERIMENTAL
Intervention: Vortex of blood flow in the main pulmonary artery
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vortex criterion diagnostic performance
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Correlation of vortex existence period with mean pulmonary arterial pressure
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Comparison of catheter-derived mean pulmonary artery pressure and calculated mean pulmonary artery pressure
Number of subjects: 48
Study: 19808512

Group type: EXPERIMENTAL
Intervention: Direct en face velocity-encoded cardiovascular magnetic resonance (veCMR)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Direct en face veCMR
Number of subjects: 44
Study: 19809305

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Activated factor XII type A (XIIaA)
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Combination of XIIaA and BNP
Number of subjects: 870
Study: 19809365

Group type: EXPERIMENTAL
Intervention: Clinical blood pressure measurements
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Self-measured blood pressure measurements
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Age-related changes in blood pressure
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Aortic pulse wave velocity
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Peripheral pulse wave velocity
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Hypertension treatment
Number of subjects: 1130
Study: 19811637

Group type: EXPERIMENTAL
Intervention: AS1402 (1-16 mg/kg) administered via intravenous infusion every 1 to 3 weeks until disease progression.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: AS1402 (1-16 mg/kg) administered via intravenous infusion.
Number of subjects: 26
Study: 19812047

Group type: EXPERIMENTAL
Intervention: Epicardial pulmonary vein isolation (PVI) using minimal invasive epicardial off-pump monolateral right-sided video-assisted thoracic surgery (VATS) with UltraCinch and high-intensity focused ultrasound (HIFU)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Epicardial pulmonary vein isolation (PVI)
Number of subjects: 15
Study: 19812176

Group type: EXPERIMENTAL
Intervention: High omega-3 LCPUFA intake (median: 0.11% of total energy intake)
Number of subjects: 1837
Study: 19812383

Group type: EXPERIMENTAL
Intervention: Busulfan (10 mg/kg)/fludarabine (180 mg/m(2))-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation
Number of subjects: 103
Study: 19812461

Group type: EXPERIMENTAL
Intervention: Memantine at a target dose of 20 mg daily for 26 weeks
Number of subjects: 43
Study: 19813252

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler ultrasonography (TCD)
Number of subjects: 192
Study: 19816190

Group type: EXPERIMENTAL
Intervention: Intralesional autologous lymphokine-activated killer (LAK) cells
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Higher numbers of CD3+/CD16+/CD56+ (T-LAK) cells in the cell products
Number of subjects: 33
Study: 19816412

Group type: EXPERIMENTAL
Intervention: Rating of perceived exertion (RPE) during submaximal aerobic exercise task
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Physiological exertion during submaximal aerobic exercise task
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Average weight regain after 1 year
Number of subjects: 113
Study: 19816674

Group type: EXPERIMENTAL
Intervention: Increased proportion of small adipose cells
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Size of mature adipose cells
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Insulin resistance
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Small adipose cells
Number of subjects: 49
Study: 19817748

Group type: EXPERIMENTAL
Intervention: Vorinostat 100 or 200 mg administered twice daily for 14 consecutive days followed by a 1-week rest interval.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vorinostat 200 mg
Number of subjects: 10
Study: 19818257

Group type: EXPERIMENTAL
Intervention: High-dose ziprasidone
Number of subjects: 0
Study: 19820236

Group type: EXPERIMENTAL
Intervention: Postoperative antithrombin (AT) activity on postoperative days (PODs) 2 and 3
Number of subjects: 1403

Group type: COMPARATOR
Intervention: Preoperative antithrombin (AT) activity
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: Occurrence of MACE
Number of subjects: 1403
Study: 19820552

Group type: EXPERIMENTAL
Intervention: Escitalopram (ESC) plus bupropion (BUP), rapid dose escalation to ESC 40 mg/day plus BUP 400 to 450 mg/day by study day 15
Number of subjects: 49
Study: 19820783

Group type: EXPERIMENTAL
Intervention: Infectious uveitis group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Noninfectious uveitis group
Number of subjects: 25
Study: 19821755

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (CGMS)
Number of subjects: 16
Study: 19822591

Group type: EXPERIMENTAL
Intervention: Purchases made in corner stores before and after school
Number of subjects: 833
Study: 19822798

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 19822896

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 73
Study: 19825163

Group type: EXPERIMENTAL
Intervention: Gait patterns (males)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Gait patterns (females)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: WOMAC questionnaire (females)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: WOMAC questionnaire (males)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: SF-36 health survey (females)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: SF-36 health survey (males)
Number of subjects: 134
Study: 19828038

Group type: EXPERIMENTAL
Intervention: Sibutramine plus lifestyle changes
Number of subjects: 10929

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 10929
Study: 19828712

Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA) diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Monounsaturated fatty acid (MUFA) diet
Number of subjects: 20
Study: 19828714

Group type: EXPERIMENTAL
Intervention: White men
Number of subjects: 1967

Group type: EXPERIMENTAL
Intervention: White women
Number of subjects: 1967

Group type: COMPARATOR
Intervention: African American men
Number of subjects: 1967

Group type: COMPARATOR
Intervention: African American women
Number of subjects: 1967
Study: 19828715

Group type: EXPERIMENTAL
Intervention: C3 polymorphism rs11569562 GG homozygotes
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: C3 polymorphism rs2250656 AA homozygotes
Number of subjects: 1754
Study: 19829297

Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg +/-20% s.c. b.i.d.)
Number of subjects: 15
Study: 19833304

Group type: EXPERIMENTAL
Intervention: Adenosine administered by intravenous infusion (140 microg/kg/min) to obtain hyperemic flow profiles.
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Patients with a history of DM (n = 22).
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Patients with newly diagnosed DM (n = 39).
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Patients with abnormal glucose tolerance (n = 58).
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Patients with normal glucose tolerance (n = 62).
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Newly diagnosed DM and a history of DM as predictors of CFR <2.
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance.
Number of subjects: 183
Study: 19833408

Group type: EXPERIMENTAL
Intervention: Confocal microscopy patterns of reticular nevi
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Confocal microscopy patterns of globular nevi
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Confocal microscopy patterns of cobblestone nevi
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Confocal follow-up study
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Confocal follow-up of globular nevi
Number of subjects: 53
Study: 19833996

Group type: EXPERIMENTAL
Intervention: Gatherers of information (female, parents, emotional support providers)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Disseminators (female first- and second-degree relatives, older or same generation family members, those with a cancer history, emotional or tangible support providers)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Blockers (spouses or partners, male first-degree relatives)
Number of subjects: 183
Study: 19834799

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 0
Study: 19835828

Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted A/Indonesia/5/2005 vaccine (single booster dose)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted A/Vietnam/1194/2004 vaccine (primed 14 months earlier)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted A/Vietnam/1194/2004 vaccine (primed 14 months earlier, two booster doses)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Un-primed control group (two doses of adjuvanted vaccine)
Number of subjects: 315
Study: 19837768

Group type: EXPERIMENTAL
Intervention: (18)F-FMT
Number of subjects: 98

Group type: COMPARATOR
Intervention: (18)F-FDG
Number of subjects: 98
Study: 19837914

Group type: EXPERIMENTAL
Intervention: Obese relative GH deficient (GHD)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Obese GH sufficient (GHS)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Normal-weight subjects
Number of subjects: 102
Study: 19837930

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion at 0.25 pmol x kg(-1) x min(-1) on day 1 and day 3
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion on day 1 and day 3
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline control on day 2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion in healthy controls on day 1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline control in healthy controls on day 2
Number of subjects: 10
Study: 19838106

Group type: EXPERIMENTAL
Intervention: IOUS-guided finger compression for demarcation of resection area
Number of subjects: 33
Study: 19838774

Group type: EXPERIMENTAL
Intervention: Rituximab therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Rituximab therapy with co-treatment
Number of subjects: 25
Study: 19841398

Group type: EXPERIMENTAL
Intervention: Coarse-grit microdermabrasion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Medium-grit microdermabrasion
Number of subjects: 40